The severe acute respiratory syndrome (SARS)-CoV-2 is an emerging viral pathogen responsible for the global coronavirus disease 2019 (COVID)-19 pandemic resulting in significant human morbidity and mortality. Based on preliminary clinical reports, hypoxic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of death. Further, septic shock, late-onset cardiac dysfunction, and multiorgan system failure are also described as contributors to overall mortality. Although extracorporeal membrane oxygenation and other modalities of mechanical cardiopulmonary support are increasingly being utilized in the treatment of respiratory and circulatory failure refractory to conventional management, their role and efficacy as support modalities in the present pandemic are unclear. We review the rapidly changing epidemiology, pathophysiology, emerging therapy, and clinical outcomes of COVID-19; and based on these data and previous experience with artificial cardiopulmonary support strategies, particularly in the setting of infectious diseases, provide consensus recommendations from ASAIO. Of note, this is a "living document," which will be updated periodically, as additional information and understanding emerges.
|Number of pages||11|
|State||Published - Jun 1 2020|
Bibliographical noteFunding Information:
Disclosure: Dr Slepian has research grants from Abiomed and NIH/ NIBIB. Dr Keller has research grant from Abiomed and NIH. Dr Bime has a research grant from NIH/NHLBI. Dr Zwischenberger has research grants from Avalon-Maquet and NIH and is an unpaid consultant for Cytosorbents; Dr El-Banayosy has a research grant from Abbott. The other authors have no conflicts of interest to report.
© 2020 Lippincott Williams and Wilkins. All rights reserved.
- extracorporeal membrane oxygenation
- mechanical circulatory support
- mechanical ventilation
ASJC Scopus subject areas
- Biomedical Engineering